Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein-Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab

JACC Cardiovasc Imaging. 2022 Apr;15(4):709-711. doi: 10.1016/j.jcmg.2021.11.014. Epub 2021 Dec 15.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Cholesterol
  • Humans
  • Lipoproteins, LDL
  • Plaque, Atherosclerotic*
  • Predictive Value of Tests
  • Proprotein Convertase 9*

Substances

  • Antibodies, Monoclonal, Humanized
  • Lipoproteins, LDL
  • Cholesterol
  • PCSK9 protein, human
  • Proprotein Convertase 9
  • evolocumab